Gene Correction of a Duchenne Muscular Dystrophy Mutation by Meganuclease-Enhanced Exon Knock-In
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Duchenne muscular dystrophy (DMD) is a severe inherited, muscle-wasting disorder caused by mutations in the DMD gene. Gene therapy development for DMD has concentrated on vector-based DMD minigene transfer, cell-based gene therapy using genetically modified adult muscle stem cells or healthy wild-type donor cells, and antisense oligonucleotide-induced exon-skipping therapy to restore the reading frame of the mutated DMD gene. This study is an investigation into DMD gene targeting-mediated correction of deletions in human patient myoblasts using a target-specific meganuclease (MN) and a homologous recombination repair matrix. The MN was designed to cleave within DMD intron 44, upstream of a deletion hotspot, and integration-competent lentiviral vectors expressing the nuclease (LVcMN) were generated. MN western blotting and deep gene sequencing for LVcMN-induced non-homologous end-joining InDels (microdeletions or microinsertions) confirmed efficient MN expression and activity in transduced DMD myoblasts. A homologous repair matrix carrying exons 45–52 (RM45–52) was designed and packaged into integration-deficient lentiviral vectors (IDLVs; LVdRM45–52). After cotransduction of DMD myoblasts harboring a deletion of exons 45 to 52 with LVcMN and LVdRM45–52 vectors, targeted knock-in of the RM45–52 region in the correct location in DMD intron 44, and expression of full-length, correctly spliced wild-type dystrophin mRNA containing exons 45–52 were observed. This work demonstrates that genome surgery on human DMD gene mutations can be achieved by MN-induced locus-specific genome cleavage and homologous recombination knock-in of deleted exons. The feasibility of human DMD gene repair in patient myoblasts has exciting therapeutic potential. Popplewell and colleagues develop a meganuclease that targets an intron upstream of many common mutations in the Duchenne muscular dystrophy (DMD) gene. They evaluate the efficiency of cleavage at this site following lentivirus vector–mediated expression of the meganuclease in DMD patient myoblasts, as well as the capacity of the meganuclease to induce recombination with a second lentivirus vector bearing the downstream DMD exons flanked by arms of homology. Using this approach, they are able to detect full-length DMD mRNA in patient myoblasts following cotransduction with the meganuclease and template-bearing vectors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome Engineering With Zinc-Finger Nucleases
Carroll, D. (2011) · Genetics · doi:10.1534/genetics.111.131433 · Cited by 1,076
Lombardo, A., Genovese, P., Beausejour, C. M., Colleoni, S., Lee, Y.-L., Kim, K. A., Ando, D., Urnov, F. D., Galli, C., Gregory, P. D., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1353 · Cited by 845
In vivo genome editing restores haemostasis in a mouse model of haemophilia
Li, H., Haurigot, V., Doyon, Y., Li, T., Wong, S. Y., Bhagwat, A. S., Malani, N., Anguela, X. M., Sharma, R., Ivanciu, L., et al. (2011) · Nature · doi:10.1038/nature10177 · Cited by 548 · cited 1×
“Gene targeting is a powerful tool for creating genetic modifications as a gene repair strategy for a variety of ge-netic diseases (Urnov et al ., 2005; Arnoud et al ., 2007; Lom-bardo et al ., 2007; Grizot et al ., 2009; Martin et al ., 2010; Carroll, 2011; Jensen et al ., 2011; Li et al ., 2011).”
Effective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460
Self-citationGenetic Fate of Recombinant Adeno-Associated Virus Vector Genomes in Muscle
Schnepp, B. C., Clark, K. R., Klemanski, D. L., Pacak, C. A., & Johnson, P. R. (2003) · Journal of Virology · doi:10.1128/jvi.77.6.3495-3504.2003 · Cited by 262 · cited 1×
“Current preclinical and clinical studies for DMD have largely concentrated on the use of AAV vector delivery of micro-dystrophin (Schnepp et al ., 2003; Liu et al ., 2005; Wang et al ., 2007a,b), exon skipping induced by antisense oligonucleotides (Jearawiriyapaisarn et al ., 2008; Cirak et al .,…”
Liu, M., Yue, Y., Harper, S. Q., Grange, R. W., Chamberlain, J. S., & Duan, D. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.09.013 · Cited by 178
Cited by
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
Genome-editing Technologies for Gene and Cell Therapy
Maeder, M. L., & Gersbach, C. A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.10 · Cited by 719
Li, H. L., Fujimoto, N., Sasakawa, N., Shirai, S., Ohkame, T., Sakuma, T., Tanaka, M., Amano, N., Watanabe, A., Sakurai, H., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.10.013 · Cited by 471
Ousterout, D. G., Kabadi, A. M., Thakore, P. I., Majoros, W. H., Reddy, T. E., & Gersbach, C. A. (2015) · Nature Communications · doi:10.1038/ncomms7244 · Cited by 470
Koo, T., Popplewell, L., Athanasopoulos, T., & Dickson, G. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.164 · Cited by 104
“Even with long, fully homologous sequences, the efficiency of HR is reported as being very low in the absence of a double-stranded breaks induced by endonucleases (Jensen et al. , 2011; Popplewell et al. , 2013).”
Self-citationThe old and the new: Prospects for non-integrating lentiviral vector technology
Apolonia, L. (2020) · Viruses · doi:10.3390/v12101103 · Cited by 58
“Other groups showed pre-clinical efficiency of ZFNs in relevant disease models, such as adenosine deaminase deficiency [101], X-SCID [102,103], and β-thalassemia [104] or meganucleases for Duchenne muscular dystrophy [105].”
Background
Metadata
- Authors
- Popplewell, L., Koo, T., Leclerc, X., Duclert, A., Mamchaoui, K., Gouble, A., Mouly, V., Voit, T., Pâques, F., Cédrone, F., Isman, O., Yáñez-Muñoz, R. J., & Dickson, G.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2013-07
- Volume
- 24
- Issue
- 7
- Pages
- 692-701
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W1983922247
- Cited by
- 65
- References
- 6
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.